| 2025-03-31 |
详情>>
内部人交易：
Fortress Biotech, Inc.股份增加33724.00股
|
| 2024-12-04 |
详情>>
股本变动：
变动后总股本205.39万股
|
| 2024-11-14 |
详情>>
业绩披露：
2024年三季报(累计)每股收益-17.27美元,归母净利润-1891.8万美元,同比去年增长-71.72%
|
| 2024-08-09 |
详情>>
业绩披露：
2024年中报每股收益-18.86美元,归母净利润-1584.2万美元,同比去年增长-37.24%
|
| 2024-05-15 |
详情>>
业绩披露：
2024年一季报每股收益-15.4美元,归母净利润-434万美元,同比去年增长42.41%
|
| 2024-05-07 |
复牌提示：
2024-05-07 11:54:21 停牌，复牌日期 2024-05-07 12:04:21
|
| 2024-05-06 |
股东大会：
将于2024-06-24召开股东大会
会议内容 ▼▲
- 1.Elect six directors for a term of one year until our 2025 Annual Meeting of Stockholders or until their successors are duly elected and qualified in accordance with our Second Amended and Restated Bylaws;
2.Ratify the appointment of KPMG LLP as our independent registered public accounting firm for the year ending December 31, 2024;
3.Approve an amendment to the 2015 Plan to increase the number of authorized shares issuable thereunder by 5,000,000 shares, which will extend the term of the 2015 Plan to June 24, 2034, increase the limit of shares that may be issued upon the exercise of incentive stock options by 5,000,000 shares, and increase the annual share limit for awards granted to non-employee directors to 500,000;
4.Transact any other business that may properly come before the Annual Meeting or any postponement or adjournment of the Annual Meeting.
|
| 2024-04-25 |
详情>>
拆分方案：
每75.0000合并分成1.0000股
|
| 2024-03-18 |
详情>>
业绩披露：
2023年年报每股收益-0.98美元,归母净利润-1037.7万美元,同比去年增长-192.15%
|
| 2023-11-13 |
详情>>
业绩披露：
2023年三季报(累计)每股收益-1.54美元,归母净利润-1101.7万美元,同比去年增长-166.95%
|
| 2023-08-11 |
详情>>
业绩披露：
2023年中报每股收益-1.73美元,归母净利润-1154.3万美元,同比去年增长-233.13%
|
| 2023-05-12 |
详情>>
业绩披露：
2023年一季报每股收益-1.35美元,归母净利润-753.6万美元,同比去年增长-163.4%
|
| 2023-04-28 |
股东大会：
将于2023-06-22召开股东大会
会议内容 ▼▲
- 1.Elect six directors for a term of one year until our 2024 Annual Meeting of Stockholders or until their successors are duly elected and qualified in accordance with our Second Amended and Restated Bylaws;
2.Ratify the appointment of KPMG LLP as our independent registered public accounting firm for the year ending December 31, 2023;
3.Approve the compensation of our named executive officers, in an advisory vote;
4.Approve the frequency with which we will hold an advisory vote on the compensation of our named executive officers, in an advisory vote;
5.Transact any other business that may properly come before the Annual Meeting or any postponement or adjournment of the Annual Meeting.
|
| 2023-03-31 |
详情>>
业绩披露：
2022年年报每股收益-1.63美元,归母净利润-355.2万美元,同比去年增长4.80%
|
| 2022-11-18 |
股东大会：
将于2022-12-28召开股东大会
会议内容 ▼▲
- 1.Elect five directors for a term of one year until our 2023 Annual Meeting of Stockholders or until their successors are duly elected and qualified in accordance with our Amended and Restated Bylaws;
2.Ratify the appointment of BDO USA, LLP as our independent registered public accounting firm for the year ending December 31, 2022;
3.Approve an amendment to our certificate of incorporation to increase the number of authorized shares of our common stock from 20,000,000 to 75,000,000;
4.Approve an amendment to our 2015 Incentive Plan to increase the number of authorized shares issuable thereunder by 5,000,000 shares;
5.Transact any other business that may properly come before the Annual Meeting or any adjournment of the Annual Meeting.
|
| 2022-11-10 |
详情>>
业绩披露：
2022年三季报(累计)每股收益-2.86美元,归母净利润-412.7万美元,同比去年增长-46.45%
|
| 2022-09-23 |
详情>>
拆分方案：
每15.0000合并分成1.0000股
|
| 2022-08-15 |
详情>>
业绩披露：
2022年中报每股收益-0.16美元,归母净利润-346.5万美元,同比去年增长-77.97%
|
| 2021-11-23 |
股东大会：
将于2021-12-16召开股东大会
会议内容 ▼▲
- 1.Elect seven directors for a term of one year;
2.Ratify the appointment of BDO USA, LLP as our independent registered public accounting firm for the year ending December 31, 2021;
3.To approve an amendment to our 2015 Equity Incentive Plan to increase the number of authorized shares issuable by 2,000,000 shares;
4.Transact any other business that may properly come before the Annual Meeting or any adjournment of the Annual Meeting.
|
| 2021-09-06 |
温馨提示：
美股因劳工节，9月6日休市一天
|
| 2020-05-29 |
股东大会：
将于2020-06-16召开股东大会
会议内容 ▼▲
- 1.Elect seven directors for a term of one year;
2.Ratify the appointment of BDO USA, LLP as our independent registered public accounting firm for the year ending December 31, 2020;
3.Transact any other business that may properly come before the Annual Meeting or any adjournment of the Annual Meeting.
|
| 2019-04-30 |
股东大会：
将于2019-06-19召开股东大会
会议内容 ▼▲
- 1.Elect seven directors for a term of one year;
2.Ratify the appointment of BDO USA, LLP as our independent registered public accounting firm for the year ending December 31, 2019;
3.Transact any other business that may properly come before the Annual Meeting or any adjournment of the Annual Meeting.
|
| 2018-12-21 |
股东大会：
将于2019-02-06召开股东大会
会议内容 ▼▲
- 1.To consider and vote on a proposal to approve and adopt the Stock Purchase and Merger Agreement, dated as of November 12, 2018, which we refer to as the “SPMA”, by and among the Company, InvaGen Pharmaceuticals Inc., a New York corporation, which we refer to as “Parent” or “Buyer”, and Madison Pharmaceuticals Inc., a Delaware corporation and a wholly-owned subsidiary of Buyer, which we refer to as “Merger Sub”, and the ancillary agreements thereto, which we refer to as the “Ancillary Agreements”, and the transactions contemplated by the SPMA and the Ancillary Agreements, including the Stock Purchase Transaction and the Merger Transaction (as defined below), and the appointment of a rights agent in connection with the contingent value rights agreement to be entered into between the Company and a rights agent (the “Appointment”), which we refer to as the “CVR Agreement”. Copies of the SPMA, the CVR Agreement and the other Ancillary Agreements are attached as Annex A to the accompanying proxy statement.
2.To consider and vote on a proposal to approve the adjournment of the special meeting, if necessary or appropriate, including to solicit additional proxies if there are insufficient votes at the time of the special meeting to approve the proposal to approve and adopt the SPMA or in the absence of a quorum.
3.To transact any other business that may properly come before the special meeting, or any adjournment or postponement of the special meeting, by or at the direction of the Board of Directors of the Company.
|
| 2018-04-30 |
股东大会：
将于2018-06-13召开股东大会
会议内容 ▼▲
- 1.Elect seven directors for a term of one year;
2.Ratify the appointment of BDO USA, LLP as our independent registered public accounting firm for the year ending December 31, 2018;
3.Approve an amendment to our Third Amended and Restated Certificate of Incorporation to amend the Annual Stock Dividend payment date from February 17 to January 1 of each year;
4.Transact any other business that may properly come before the Annual Meeting or any adjournment of the Annual Meeting.
|